Table 2.
Treatment† | Experiment | Incidence | Day of onset‡ | Day of maximal arthritis score‡ | Maximal arthritis score‡ | Sum score‡ | Log rank test§ |
---|---|---|---|---|---|---|---|
D10 | 1 | 5/6 | 12 | 17 | 5 | 52 | NS* |
NKR-P1 | 1 | 6/7 | 14 | 18 | 6 | 41 | |
D10 | 2 | 7/7 | 12 | 20 | 7 | 57 | 0·048 |
NKR-P1 | 2 | 5/7 | 14 | 18 | 6 | 61 | |
D10 | 3 | 5/7 | 14 | 20 | 4 | 19 | NS |
NKR-P1 | 3 | 6/7 | 13 | 17 | 5 | 30 |
1 mg anti-NKR-P1 MoAb (clone 10/78) or isotype-matched control MoAb (clone D10) was administered to DA rats 2 days before induction of OIA.
Median value of affected animals.
P value when testing the null hypothesis that there is no difference between the groups when taking the whole disease progress into account, using the survival analysis log-rank test.
Not significant.